Evidence map›Paper›PMID 34258576›Full record

ArticleVaccine: X2021

Invaplex functions as an intranasal adjuvant for subunit and DNA vaccines co-delivered in the nasal cavity of nonhuman primates.

Jeremy V Camp, Robert L Wilson, Morgan Singletary, James L Blanchard, Anna Aldovini, Robert W Kaminski, Edwin V Oaks, Pamela A Kozlowski

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Jeremy V CampDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Robert L WilsonDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Morgan SingletaryTulane National Primate Research Center, Division of Veterinary Medicine, Covington, LA 70433, USA.
James L BlanchardTulane National Primate Research Center, Division of Veterinary Medicine, Covington, LA 70433, USA.
Anna AldoviniDepartments of Medicine and Pediatrics, Children's Hospital and Harvard, Boston, MA 02115, USA.
Robert W KaminskiDepartment of Subunit Enteric Vaccines and Immunology, Division of Bacterial and Rickettsial Diseases, The Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Edwin V OaksDepartment of Subunit Enteric Vaccines and Immunology, Division of Bacterial and Rickettsial Diseases, The Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Pamela A KozlowskiDepartment of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Louisiana State University Health Sciences Center New Orleans · USTulane University · USWalter Reed Army Institute of Research · USBoston Children's Hospital · US

Funding

ZCM:A NOVEL BROAD-SPECTRUM MICROBICIDE FOR SEXUALLY TRANSMITTED INFECTIONSP51RR000164 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI VEAZEY, RONALD S. · 1985 to 2011
$100.1M
HIV and SIV Vaccines and Mucosal ImmunityR01AI041365 · NIAID · CHILDREN'S HOSPITAL BOSTON · PI ALDOVINI, ANNA · 1997 to 2005
$3.9M
NASAL DNA/PROTEIN VACCINE FOR ANTI-HIV ANTIBODY AND CTLR01AI058896 · NIAID · LSU HEALTH SCIENCES CENTER · PI KOZLOWSKI, PAMELA ANN · 2004 to 2009
$2.6M
HIV and SIV DNA Vaccines and Mucosal ImmunityR56AI041365 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI ALDOVINI, ANNA · 2007 to 2007
$632k
NCRR NIH HHS P51 RR000164NIAID NIH HHS R01 AI041365NIAID NIH HHS R01 AI058896NIAID NIH HHS R56 AI041365
6 · The paper itself

Abstract

Development of intranasal vaccines for HIV-1 and other mucosal pathogens has been hampered by the lack of adjuvants that can be given safely to humans. We have found that an intranasal Shigella vaccine (Invaplex) which is well tolerated in humans can also function as an adjuvant for intranasal protein and DNA vaccines in mice. To determine whether Invaplex could potentially adjuvant similar vaccines in humans, we simultaneously administered a simian immunodeficiency virus (SIV) envelope (Env) protein and DNA encoding simian-human immunodeficiency virus (SHIV) with or without Invaplex in the nasal cavity of female rhesus macaques. Animals were intranasally boosted with adenoviral vectors expressing SIV

Indexed as

Ad, adenovirusCVS, cervicovaginal secretionsEnv, envelopeHIV/AIDSICS, intracellular cytokine stainingIgAIM, intramuscularIN, intranasalMucosal adjuvantNHP, nonhuman primatesNS, nasal secretionsReproductiveRespiratory tractRS, rectal secretionsS-IgA, secretory IgATh, T helper

Identifiers

PMID34258576
PMCPMC8255935
OpenAlexW3175905336

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.